CG
NBIX icon

Caprock Group’s Neurocrine Biosciences NBIX Stock Holding History

Caprock Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$555K Buy
3,295
+938
+40% +$139K 0.01% 816
2026
Q1 		$311K Buy
+2,357
New +$313K 0.01% 907
2025
Q1 		$259K Buy
2,346
+619
+36% +$78.4K 0.01% 921
2024
Q4 		$236K Buy
+1,727
New +$214K 0.01% 880
2024
Q3 		– Sell
-1,669
Closed -$230K – 954
2024
Q2 		$230K Buy
1,669
+109
+7% +$14.9K 0.01% 765
2024
Q1 		$215K Buy
+1,560
New +$213K 0.01% 659
2018
Q3 		– Sell
-2,712
Closed -$266K – 430
2018
Q2 		$266K Sell
2,712
-11
-0.4% -$985 0.06% 318
2018
Q1 		$226K Buy
+2,723
New +$230K 0.05% 358

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Caprock Group's NBIX Position: Q2 2026 in Review

Caprock Group increased its Neurocrine Biosciences (NBIX) stake by 40% in Q2 2026, buying an estimated $139K and bringing the position to 3,295 shares worth $555K. The position accounts for 0.01% of the portfolio, ranked #816.

Caprock Group first reported a position in NBIX in Q1 2018 and has held it in 8 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Caprock Group held 3,295 shares of Neurocrine Biosciences worth $555K as of Q2 2026.
  • Caprock Group bought 938 Neurocrine Biosciences shares in Q2 2026, an estimated $139K.
  • Neurocrine Biosciences made up 0.01% of Caprock Group's portfolio in Q2 2026, its #816 holding.
  • Caprock Group first reported a position in Neurocrine Biosciences in Q1 2018 and has held it in 8 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Caprock Group's 13F filing for Q2 2026, filed 27 Jul 2026.